Peter Orzack (citi) on the economics and financing of health. Gave interesting insights into potential unintended consequences of transparency (aside from reduced variation), could get collusion.
Drugs and devices require RCT level evidence to be enacted, but health financing policy can be done from the hip.
Risk adjustment will be improved by clinical (EMR) level data. At present, claims-based risk adjustment can predict only 10% of future spending whereas clinical data + SES data can predict 40%
Note “Micro Kale” on the menu:
Mark T. Bertolini, CEO of Aetna, presenting one of the most powerful speeches on health care reform and renewal of corporate america I’ve every heard.
Also had an extended conversation over dinner with Ceci Connolly (MD, PWC Health) spoke with Halle Tecco (CEO, Rock Health) and Luc Sirois (Hacking Health, coming to HISA’s HIC 2015), Dr Paul Tang (Paolo Alto Medical Foundation) and Kaiser Permanente (polypill work).